A study to investigate how well BI 764532, at different doses, is tolerated by individuals with DLL3-positive brain tumors

This study has two parts, Part A (dose escalation) and Part B (dose expansion). This information and consent form is for study participants who are participating in Part A (dose escalation).
Part A of this study aims to determine how well different doses of the investigational drug BI 764532 are tolerated by patients with a brain tumor that is positive for a tumor marker called "DLL3" and has progressed after treatment with standard therapies.
Part A of this study will also evaluate how effective the treatment is based on clinical response (whether it can treat your tumor or prevent it from worsening), as well as based on various biomarkers (characteristics of the body that can be measured) in the blood and tumor tissue. It will also test how quickly or slowly the investigational drug is processed by your body and eliminated.
The collected data were used to determine the recommended dose for Part B (dose expansion) of the study.
In Part B (dose expansion), it will now be further evaluated how well the recommended dose indicated in Part A (dose escalation) is tolerated. As in Part A of this study, Part B will also evaluate the effectiveness of the treatment based on clinical response (whether it can treat your tumor or prevent worsening) as well as based on various biomarkers (body characteristics that can be measured) in the blood and tumor tissue. It will also test how quickly or slowly the investigational drug is processed by your body and eliminated.

In this study, we want to find out what effect the investigational drug BI 764532 has on patients with tumor tissue confirmed as DLL3-positive.

DLL3-positive brain tumors